Combination therapy for the treatment of pancreatic cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 5, 2011, Pages 418-426

  Greenhalf, William ^a   Thomas, Amy ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Apoptosis; Chemotherapy; Combination therapy; Drug resistance; Novel therapy; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Pathways; Targets; Toxicity; Tumour microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE; ERLOTINIB; FLUOROURACIL; GELDANAMYCIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; K RAS PROTEIN; LONAFARNIB; OXALIPLATIN; PHA 793887; UNCLASSIFIED DRUG; Z 360;

APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL STRESS; DNA SYNTHESIS; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME METABOLISM; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; STROMA CELL; THROMBOCYTOPENIA;

EID: 79958124135     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011795677391     Document Type: Article

References (78)

1. Mossner, J., What's New in Therapy of Pancreatic Cancer? Dig. Dis., 2010, 28 (4-5), 679-683.
2. Kerem, E.; Hirawat, S.; Armoni, S.; Yaakov, Y.; Shoseyov, D.; Cohen, M.; Nissim-Rafinia, M.; Blau, H.; Rivlin, J.; Aviram, M.; Elfring, G. L.; Northcutt, V. J.; Miller, L. L.; Kerem, B.; Wilschanski, M., Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet,2008, 372 (9640), 719-727.
3. Active Biochem: PTC124. http://www.activebiochem.com/Product/PTC-124.html (accessed April 13, 2011).
4. Granio, O.; Ashbourne Excoffon, K. J.; Henning, P.; Melin, P.; Norez, C.; Gonzalez, G.; Karp, P. H.; Magnusson, M. K.; Habib, N.; Lindholm, L.; Becq, F.; Boulanger, P.; Zabner, J.; Hong, S. S., Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia. Hum. Gene Ther., 2010, 21 (3), 251-269.
5. Neoptolemos, J. P.; Stocken, D. D.; Friess, H.; Bassi, C.; Dunn, J.A.; Hickey, H.; Beger, H.; Fernandez-Cruz, L.; Dervenis, C.; Lacaine, F.; Falconi, M.; Pederzoli, P.; Pap, A.; Spooner, D.; Kerr, D. J.; Buchler, M. W., A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med., 2004, 350 (12), 1200-1210.
6. Neoptolemos, J.; Büchler, M.; Stocken, D. D.; Ghaneh, P.; Smith, D.; Bassi, C.; Moore, M.; Cunningham, D.; Dervenis, C.; Goldstein, D., ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J. Clin. Oncol., 2009, 27, 18S abstr LBA4505.
7. Burris, H. A., 3rd; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; Von Hoff, D. D., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15 (6), 2403-2413.
8. Cunningham, D.; Chau, I.; Stocken, D. D.; Valle, J. W.; Smith, D.; Steward, W.; Harper, P. G.; Dunn, J.; Tudur-Smith, C.; West, J.; Falk, S.; Crellin, A.; Adab, F.; Thompson, J.; Leonard, P.; Ostrowski, J.; Eatock, M.; Scheithauer, W.; Herrmann, R.; Neoptolemos, J. P., Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 2009, 27 (33), 5513-5518.
9. Tsujie, M.; Nakamori, S.; Nakahira, S.; Takahashi, Y.; Hayashi, N.; Okami, J.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Monden, M., Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res., 2007, 27 (4B), 2241-2249.
10. Nakano, Y.; Tanno, S.; Koizumi, K.; Nishikawa, T.; Nakamura, K.; Minoguchi, M.; Izawa, T.; Mizukami, Y.; Okumura, T.; Kohgo, Y., Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br.J. Cancer, 2007, 96 (3), 457-463.
11. Nishio, R.; Tsuchiya, H.; Yasui, T.; Matsuura, S.; Kanki, K.; Kurimasa, A.; Hisatome, I.; Shiota, G., Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Sci., 2011, 102 (3), 622-629.
12. Marechal, R.; Mackey, J. R.; Lai, R.; Demetter, P.; Peeters, M.; Polus, M.; Cass, C. E.; Young, J.; Salmon, I.; Deviere, J.; Van Laethem, J. L., Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res., 2009, 15 (8), 2913-2919.
13. Farrell, J. J.; Elsaleh, H.; Garcia, M.; Lai, R.; Ammar, A.; Regine, W. F.; Abrams, R.; Benson, A. B.; Macdonald, J.; Cass, C. E.; Dicker, A. P.; Mackey, J. R., Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology, 2009, 136 (1), 187-195.
14. Lam, W.; Leung, C. H.; Bussom, S.; Cheng, Y. C., The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine. Mol. Pharmacol., 2007, 72 (3), 536-544.
15. Casanello, P.; Torres, A.; Sanhueza, F.; Gonzalez, M.; Farias, M.; Gallardo, V.; Pastor-Anglada, M.; San Martin, R.; Sobrevia, L., Equilibrative nucleoside transporter 1 expression is down regulated by hypoxia in human umbilical vein endothelium. Circ. Res., 2005, 97 (1), 16-24.
16. Olive, K. P.; Jacobetz, M. A.; Davidson, C. J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M. A.; Caldwell, M. E.; Allard, D.; Frese, K. K.; Denicola, G.; Feig, C.; Combs, C.; Winter, S. P.; Ireland-Zecchini, H.; Reichelt, S.; Howat, W. J.; Chang, A.; Dhara, M.; Wang, L.; Ruckert, F.; Grutzmann, R.; Pilarsky, C.; Izeradjene, K.; Hingorani, S. R.; Huang, P.; Davies, S. E.; Plunkett, W.; Egorin, M.; Hruban, R. H.; Whitebread, N.; McGovern, K.; Adams, J.; Iacobuzio-Donahue, C.; Griffiths, J.; Tuveson, D. A., Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 2009, 324 (5933), 1457-1461.
17. Neesse, A.; Michl, P.; Frese, K. K.; Feig, C.; Cook, N.; Jacobetz, M. A.; Lolkema, M. P.; Buchholz, M.; Olive, K. P.; Gress, T. M.; Tuveson, D. A., Stromal biology and therapy in pancreatic cancer. Gut, 2010.
18. Kraman, M.; Bambrough, P. J.; Arnold, J. N.; Roberts, E. W.; Magiera, L.; Jones, J. O.; Gopinathan, A.; Tuveson, D. A.; Fearon, D. T., Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 2010, 330 (6005), 827-830.
19. Grippo, P. J.; Tuveson, D. A., Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev. Res. (Phila), 2010, 3 (11), 1382-1387.
20. McAllister, S. S.; Gifford, A. M.; Greiner, A. L.; Kelleher, S. P.; Saelzler, M. P.; Ince, T. A.; Reinhardt, F.; Harris, L. N.; Hylander, B. L.; Repasky, E. A.; Weinberg, R. A., Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell, 2008, 133 (6), 994-1005.
21. Ben, Q. W.; Jin, X. L.; Liu, J.; Cai, X.; Yuan, F.; Yuan, Y. Z., Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer. Oncol. Rep., 2011, 25 (3), 709-716.
22. Erkan, M.; Kleeff, J.; Gorbachevski, A.; Reiser, C.; Mitkus, T.; Esposito, I.; Giese, T.; Buchler, M. W.; Giese, N. A.; Friess, H., Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology, 2007, 132 (4), 1447-1464.
23. Kanno, A.; Satoh, K.; Masamune, A.; Hirota, M.; Kimura, K.; Umino, J.; Hamada, S.; Satoh, A.; Egawa, S.; Motoi, F.; Unno, M.; Shimosegawa, T., Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int. J. Cancer, 2008, 122 (12), 2707-2718.
24. Ina, S.; Hirono, S.; Noda, T.; Yamaue, H., Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance. Pancreas, 2010, 39 (4), 473-485.
25. Komori, S.; Osada, S.; Mori, R.; Matsui, S.; Sanada, Y.; Tomita, H.; Tokuyama, Y.; Takahashi, T.; Yamaguchi, K.; Yoshida, K., Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer. Pancreas, 2010, 39 (8), 1284-1292.
26. Yuan, Z.; Sanders, A. J.; Ye, L.; Wang, Y.; Jiang, W. G., Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. Anticancer Res., 2011, 31 (1), 303-310.
27. Yoo, C.; Hwang, J. Y.; Kim, J. E.; Kim, T. W.; Lee, J. S.; Park, D. H.; Lee, S. S.; Seo, D. W.; Lee, S. K.; Kim, M. H.; Han, D. J.; Kim, S. C.; Lee, J. L., A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br. J. Cancer, 2009, 101 (10), 1658-1663.
28. Costantino, C. L.; Witkiewicz, A. K.; Kuwano, Y.; Cozzitorto, J. A.; Kennedy, E. P.; Dasgupta, A.; Keen, J. C.; Yeo, C. J.; Gorospe, M.; Brody, J. R., The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res., 2009, 69 (11), 4567-4572.
29. Schniewind, B.; Christgen, M.; Kurdow, R.; Haye, S.; Kremer, B.; Kalthoff, H.; Ungefroren, H., Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int. J. Cancer, 2004, 109 (2), 182-188.
30. Xu, Z. W.; Friess, H.; Buchler, M. W.; Solioz, M., Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother. Pharmacol., 2002, 49 (6), 504-510.
31. Hwang, J. H.; Voortman, J.; Giovannetti, E.; Steinberg, S. M.; Leon, L. G.; Kim, Y. T.; Funel, N.; Park, J. K.; Kim, M. A.; Kang, G. H.; Kim, S. W.; Del Chiaro, M.; Peters, G. J.; Giaccone, G., Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE, 2010, 5 (5), e10630.
32. Liau, S. S.; Whang, E., HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin. Cancer Res., 2008, 14 (5), 1470-1477.
33. Abe, N.; Watanabe, T.; Masaki, T., Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res., 2000, 60, 3117-3122.
34. Ng, S.; Tsao, M.; Nicklee, T.; Hedley, D., Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res., 2001, 7, 3269-3275.
35. Yonemori, K.; Ueno, H.; Okusaka, T.; Yamamoto, N.; Ikeda, M.; Saijo, N.; Yoshida, T.; Ishii, H.; Furuse, J.; Sugiyama, E.; Kim, S. R.; Kikura-Hanajiri, R.; Hasegawa, R.; Saito, Y.; Ozawa, S.; Kaniwa, N.; Sawada, J., Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res., 2005, 11 (7), 2620-2624.
36. Sugiyama, E.; Kaniwa, N.; Kim, S. R.; Kikura-Hanajiri, R.; Hasegawa, R.; Maekawa, K.; Saito, Y.; Ozawa, S.; Sawada, J.; Kamatani, N.; Furuse, J.; Ishii, H.; Yoshida, T.; Ueno, H.; Okusaka, T.; Saijo, N., Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol., 2007, 25 (1), 32-42.
37. Almoguera, C.; Shibata, D.; Forrester, K.; Martin, J.; Arnheim, N.; Perucho, M., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 1988, 53 (4), 549-554.
38. Ito, T.; Kawata, S.; Tamura, S.; Igura, T.; Nagase, T.; Miyagawa, J. I.; Yamazaki, E.; Ishiguro, H.; Matasuzawa, Y., Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn. J. Cancer Res., 1996, 87 (2), 113-116.
39. Liu, M.; Bryant, M. S.; Chen, J.; Lee, S.; Yaremko, B.; Lipari, P.; Malkowski, M.; Ferrari, E.; Nielsen, L.; Prioli, N.; Dell, J.; Sinha, D.; Syed, J.; Korfmacher, W. A.; Nomeir, A. A.; Lin, C. C.; Wang, L.; Taveras, A. G.; Doll, R. J.; Njoroge, F. G.; Mallams, A. K.; Remiszewski, S.; Catino, J. J.; Girijavallabhan, V. M.; Bishop, W. R., et al., Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res., 1998, 58 (21), 4947-4956.
40. Nakajima, A.; Tauchi, T.; Sumi, M.; Bishop, W. R.; Ohyashiki, K., Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol. Cancer Ther., 2003, 2 (3), 219-224.
41. Macdonald, J. S.; McCoy, S.; Whitehead, R. P.; Iqbal, S.; Wade, J. L., 3rd; Giguere, J. K.; Abbruzzese, J. L., A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs, 2005, 23 (5), 485-487.
42. Whyte, D. B.; Kirschmeier, P.; Hockenberry, T. N.; Nunez-Oliva, I.; James, L.; Catino, J. J.; Bishop, W. R.; Pai, J. K., K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 1997, 272 (22), 14459-14464.
43. Selleck Novel Life Science Reagents: PHA-793887. http://www.selleckchem.com/products/PHA-793887.html (accessed April 12, 2011).
44. Brasca, M. G.; Albanese, C.; Alzani, R.; Amici, R.; Avanzi, N.; Ballinari, D.; Bischoff, J.; Borghi, D.; Casale, E.; Croci, V.; Fiorentini, F.; Isacchi, A.; Mercurio, C.; Nesi, M.; Orsini, P.; Pastori, W.; Pesenti, E.; Pevarello, P.; Roussel, P.; Varasi, M.; Volpi, D.; Vulpetti, A.; Ciomei, M., Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med. Chem., 2010, 18 (5), 1844-1853.
45. Friess, H.; Wang, L.; Zhu, Z.; Gerber, R.; Schroder, M.; Fukuda, A.; Zimmermann, A.; Korc, M.; Buchler, M. W., Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Annals Surg., 1999, 230 (6), 767-774; discussion 774-775.
46. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25 (15), 1960-1966.
47. Von Marschall, Z.; Cramer, T.; Hocker, M.; Burde, R.; Plath, T.; Schirner, M.; Heidenreich, R.; Breier, G.; Riecken, E. O.; Wiedenmann, B.; Rosewicz, S., De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology, 2000, 119 (5), 1358-1372.
48. Ko, A. H.; Venook, A. P.; Bergsland, E. K.; Kelley, R. K.; Korn, W. M.; Dito, E.; Schillinger, B.; Scott, J.; Hwang, J.; Tempero, M. A., A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother. Pharmacol., 2010, 66 (6), 1051-1057.
49. Jones, S.; Zhang, X.; Parsons, D. W.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S. M.; Fu, B.; Lin, M. T.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J. R.; Kern, S. E.; Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008, 321 (5897), 1801-1806.
50. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G., Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008.
51. Xu, W.; Neckers, L., Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res., 2007, 13 (6), 1625-1629.
52. Neckers, L.; Ivy, S. P., Heat shock protein 90. Curr. Opin. Oncol., 2003, 15 (6), 419-424.
53. Burkitt, M.; Magee, C.; O'Connor, D.; Campbell, F.; Cornford, P.; Greenhalf, W., Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. Mol. Carcinog., 2007, 46 (6), 466-475.
54. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I., Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol., 2005, 23 (18), 4152-4161.
55. Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C. G.; Sun, D., A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther., 2008, 7 (1), 162-170.
56. Sultana, A.; Ghaneh, P.; Cunningham, D.; Starling, N.; Neoptolemos, J. P.; Smith, C. T., Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer, 2008, 8, 192.
57. Chua, Y. J.; Zalcberg, J. R., Pancreatic cancer--is the wall crumbling? Ann Oncol 2008, 19 (7), 1224-1230.
58. Nakachi, K.; Furuse, J.; Kinoshita, T.; Kawashima, M.; Ishii, H.; Ikeda, M.; Mitsunaga, S.; Shimizu, S., A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Cancer Chemother. Pharmacol., 2010, 66 (3), 527-534.
59. Kawashima, H.; Itoh, A.; Ohno, E.; Nakamura, M.; Miyahara, R.; Ohmiya, N.; Hara, K.; Kanamori, A.; Itoh, T.; Taki, T.; Hirai, T.; Hashimoto, S.; Takeda, K.; Goto, H.; Hirooka, Y. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Cancer Chemother. Pharmacol., 2010. [EPub Ahead of Print]
60. Feliu, J.; Borrega, P.; Leon, A.; Lopez-Gomez, L.; Lopez, M.; Castro, J.; Belda-Iniesta, C.; Barriuso, J.; Martinez, V.; Gonzalez-Baron, M., Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemother. Pharmacol., 2010, 67, 215-221.
61. Meyer, T.; Caplin, M. E.; Palmer, D. H.; Valle, J. W.; Larvin, M.; Waters, J. S.; Coxon, F.; Borbath, I.; Peeters, M.; Nagano, E.; Kato, H., A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. Eur. J. Cancer., 2010, 46 (3), 526-533.
62. Kawasaki, D.; Emori, Y.; Eta, R.; Iino, Y.; Hamano, H.; Yoshinaga, K.; Tanaka, T.; Takei, M.; Watson, S. A., Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother. Pharmacol., 2008, 61 (5), 883-892.
63. Gore, L.; Holden, S. N.; Cohen, R. B.; Morrow, M.; Pierson, A. S.; O'Bryant, C. L.; Persky, M.; Gustafson, D.; Mikule, C.; Zhang, S.; Palmer, P. A.; Eckhardt, S. G., A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Ann. Oncol.,2006, 17 (11), 1709-1717.
64. Saif, M. W.; Kim, R., Role of platinum agents in the management of advanced pancreatic cancer. Expert Opinion on Pharmacotherapy, 2007, 8 (16), 2719-27.
65. Colucci, G.; Giuliani, F.; Gebbia, V.; Biglietto, M.; Rabitti, P.; Uomo, G.; Cigolari, S.; Testa, A.; Maiello, E.; Lopez, M., Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer, 2002, 94 (4), 902-910.
66. Xiros, N.; Papacostas, P.; Economopoulos, T., Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a Phase II multicenter study by the Hellenic cooperative oncology group. Ann. Oncol., 2005, 16 (5), 773-779.
67. Demols, A.; Peeters, M.; Polus, M.; Marechal, R.; Gay, F.; Monsaert, E.; Hendlisz, A.; Van Laethem, J. L., Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br. J. Cancer, 2006, 94 (4), 481-5.
68. Gutt, R.; Liauw, S. L.; Weichselbaum, R. R., The role of radiotherapy in locally advanced pancreatic carcinoma. Nat. Rev. Gastroenterol. Hepatol., 2010, 7 (8), 437-447.
69. Willett, C. G.; Duda, D. G.; di Tomaso, E.; Boucher, Y.; Ancukiewicz, M.; Sahani, D. V.; Lahdenranta, J.; Chung, D. C.; Fischman, A. J.; Lauwers, G. Y.; Shellito, P.; Czito, B. G.; Wong, T. Z.; Paulson, E.; Poleski, M.; Vujaskovic, Z.; Bentley, R.; Chen, H. X.; Clark, J. W.; Jain, R. K., Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol., 2009, 27 (18), 3020-3026.
70. Butturini, G.; Stocken, D. D.; Wente, M. N.; Jeekel, H.; Klinkenbijl, J. H.; Bakkevold, K. E.; Takada, T.; Amano, H.; Dervenis, C.; Bassi, C.; Buchler, M. W.; Neoptolemos, J. P., Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch. Surg., 2008, 143 (1), 75-83; discussion 83.
71. Shinchi, H.; Takao, S.; Noma, H.; Matsuo, Y.; Mataki, Y.; Mori, S.; Aikou, T., Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys., 2002, 53 (1), 146-150.
72. Chauffert, B.; Mornex, F.; Bonnetain, F.; Rougier, P.; Mariette, C.; Bouche, O.; Bosset, J. F.; Aparicio, T.; Mineur, L.; Azzedine, A.; Hammel, P.; Butel, J.; Stremsdoerfer, N.; Maingon, P.; Bedenne, L., Phase III trial comparing intensive induction chemoradio-therapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol., 2008, 19 (9), 1592-1599.
73. Morak, M. J.; Hermans, J. J.; Smeenk, H. G.; Renders, W. M.; Nuyttens, J. J.; Kazemier, G.; van Eijck, C. H., Staging for locally advanced pancreatic cancer. Eur. J. Surg. Oncol., 2009, 35 (9), 963-968.
74. Infinity Pharmaceuticals: IPI-926. http://www.infi.com/product-candidates-pipeline-ipi-926.asp (accessed April 22, 2011).
75. Bai, J.; Sata, N.; Nagai, H., Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford) 2007, 9 (2), 150-155.
76. Palombella, V. J.; Conner, E. M.; Fuseler, J. W.; Destree, A.; Davis, J. M.; Laroux, F. S.; Wolf, R. E.; Huang, J.; Brand, S.; Elliott, P. J.; Lazarus, D.; McCormack, T.; Parent, L.; Stein, R.; Adams, J.; Grisham, M. B., Role of the proteasome and NF-kappa B in streptococcal cell wall-induced polyarthritis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95 (26), 15671-15676.
77. Smith, M. A.; Morton, C. L.; Phelps, D. A.; Kolb, E. A.; Lock, R.; Carol, H.; Reynolds, C. P.; Maris, J. M.; Keir, S. T.; Wu, J.; Houghton, P. J., Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2008, 51 (1), 34-41.
78. Ramanathan, R. K.; Trump, D. L.; Eiseman, J. L.; Belani, C. P.; Agarwala, S. S.; Zuhowski, E. G.; Lan, J.; Potter, D. M.; Ivy, S. P.; Ramalingam, S.; Brufsky, A. M.; Wong, M. K.; Tutchko, S.; Egorin, M. J., Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res., 2005, 11 (9), 3385-3391.